Gilead acquires CAR-T specialist Arcellx for $7.8bn

Group 1: Acquisition Details - Gilead has agreed to acquire Arcellx for $7.8 billion, aiming to enhance its portfolio with a CAR T-cell therapy for blood cancer treatment that is nearing approval [1] - The acquisition involves a payment of $115 per share and a contingent value right (CVR) of $5 each, with the deal expected to close in Q2 2026 [1][2] Group 2: Background and Collaboration - The acquisition follows a collaboration between Gilead and Arcellx, initiated in 2022, where Gilead's subsidiary Kite partnered with Arcellx to develop anito-cel, a CAR T-cell therapy for multiple myeloma [2] - Gilead currently holds an 11.5% share in Arcellx after investing further in 2023 [2] Group 3: Product and Market Potential - Anito-cel is under FDA review with a Prescription Drug User Fee Act (PDUFA) action date set for December 23, 2026, and if approved, it will serve as a fourth-line treatment for relapsed or refractory multiple myeloma [3] - The CVR will be activated if global sales of anito-cel reach $6 billion by the end of 2029, with analysts projecting cumulative global sales of $7.8 billion by that time [3][4] Group 4: Strategic Importance - Gilead's CEO emphasized the potential of anito-cel and the company's commitment to expedite its development for multiple myeloma patients [4] - Anito-cel could evolve into a foundational treatment for multiple myeloma and may enhance Gilead's capabilities in oncology and inflammation [5] Group 5: Industry Trends - The CAR T-cell therapy market is witnessing a shift towards in vivo therapies, which are gaining interest from pharmaceutical companies as the future of cell and gene therapy (CGT) [6] - Recent M&A activity in the CAR-T space includes significant deals by Eli Lilly, Bristol Myers Squibb, and AbbVie, focusing on in vivo therapies [7]